SEC Form 4 · accession 0001209191-18-017207
TEVA PHARMACEUTICAL INDUSTRIES LTD · TEVA
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Hafrun Fridriksdottir
Officer — Executive VP, Global R&D
Period of report
Mar 4, 2018
Accepted (ET)
Mar 6, 2018 · 4:12 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0000818686
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Ordinary SharesF1,F2 | Mar 4, 2018 | M | 1,165 | — | A | 4,510 | D | |
| Ordinary SharesF1,F2 | Mar 5, 2018 | M | 3,432 | — | A | 7,942 | D | |
| Ordinary SharesF1 | Mar 5, 2018 | F | 400 | $19.38 | D | 7,542 | D | |
| Ordinary SharesF1 | Mar 5, 2018 | F | 1,155 | $19.38 | D | 6,387 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Restricted Share UnitsF2,F3,F1 | — | Mar 4, 2018 | M | 1,165 | D | — | — | Ordinary Shares | 1,165 | 1,165 | D |
| Restricted Share UnitsF2,F4,F1 | — | Mar 5, 2018 | M | 3,432 | D | — | — | Ordinary Shares | 3,432 | 0 | D |
Explanation of responses
- F1The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share.
- F2Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share.
- F3Restricted share units were granted on March 4, 2015, with 1,165 vesting on each of March 4, 2018 and March 4, 2019.
- F4Restricted share units were granted on May 8, 2014 and vest on March 5, 2018.